CompletedNot Applicable

Efficacy of Eye Movement Desensitization and Reprocessing (EMDR) Therapy Versus Selective Serotonin Reuptake Inhibitors (SSRIs) in the Treatment of Post-Traumatic Stress Disorder

Pakistan60 participantsStarted 2025-05-06

Plain-language summary

This randomized controlled trial aims to compare the efficacy of Eye Movement Desensitization and Reprocessing (EMDR) therapy versus Selective Serotonin Reuptake Inhibitors (SSRIs) in the treatment of Post-Traumatic Stress Disorder (PTSD). Adult patients diagnosed with PTSD will be randomly assigned to receive either EMDR therapy or SSRIs for a period of six weeks. The primary outcome is the rate of remission as measured by validated PTSD symptom severity scales at Week 6. Secondary outcomes include changes in functional impairment and patient-reported quality of life. The study seeks to determine whether EMDR therapy is a non-pharmacological alternative to SSRIs for achieving symptom remission in PTSD.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Age 18-60 years Clinical diagnosis of Post-Traumatic Stress Disorder (PTSD) Duration of illness ≥ 6 months Able to provide informed consent Exclusion Criteria: Current substance abuse or dependence History of psychotic disorder or bipolar disorder Active suicidal ideation Concurrent psychotherapy or psychiatric medication (except study-assigned SSRI)

What they're measuring

Remission rate at Week 6

Timeframe: 6 weeks

Trial details

NCT IDNCT06955845

SponsorAsad Ullah Jan

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2025-11-30

View on ClinicalTrials.gov More PTSD trials